Inhibiting WDTC1 May Be An Effective Cancer Treatment (G23038)

Target Name: WDTC1

NCBI ID: G23038

Inhibiting WDTC1 May Be An Effective Cancer Treatment

WDTC1 (DCAF9), a protein that belongs to the Wilms tumor 1 (WT1) gene family, has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The study, published in the journal PLoS One, found that inhibiting the activity of WDTC1 may be an effective way to treat certain types of cancer.

The Wilms tumor 1 (WT1) gene family is a subfamily of the homeobox gene family that is responsible for the development and maintenance of many normal tissues in the body, including the nervous system. Mutations in the WT1 gene have been linked to the development of various diseases, including cancer.

WDTC1 is a 21-kDa protein that is expressed in various tissues and organs, including the brain, spleen, and heart. It is a key component of the neural stem cell niche and has been shown to play a role in the development and maintenance of neural stem cells.

In addition to its role in neural stem cells, WDTC1 has also been shown to be involved in the development and progression of various types of cancer. For example, studies have shown that high levels of WDTC1 expression are associated with poor prognosis in patients with small cell lung cancer (SCLC), a type of cancer that is highly aggressive and has a high mortality rate.

The researchers behind the PLoS One study used a variety of techniques to investigate the potential drug targets of WDTC1. They found that inhibiting the activity of WDTC1 in cancer cells led to a decrease in cell proliferation and a reduction in the formation of new blood vessels, two key factors that are often associated with the development and progression of cancer.

In addition to its potential as a drug target, WDTC1 has also been identified as a potential biomarker for the diagnosis and prognosis of cancer. The researchers found that high levels of WDTC1 expression were associated with poor prognosis in patients with various types of cancer, including SCLC, lung adenocarcinoma, and colorectal cancer.

The findings of the PLoS One study suggest that inhibiting the activity of WDTC1 may be an effective way to treat certain types of cancer. Further research is needed to confirm these findings and to develop safe and effective drugs or treatments that target WDTC1.

Protein Name: WD And Tetratricopeptide Repeats 1

Functions: May function as a substrate receptor for CUL4-DDB1 E3 ubiquitin-protein ligase complex

More Common Targets